Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Weichenthal

Showing results (81-90 of 167) with videos related to

Pageof 17
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 28, 2015
Intermittent High-Dose Intravenous Interferon Alfa-2b for Adjuvant Treatment of Stage III Melanoma: Final Analysis of a Randomized Phase III Dermatologic Cooperative Oncology Group TrialPeter Mohr, Axel Hauschild, Uwe Trefzer, et al.
Cancers|November 26, 2022
Response to First-Line Treatment with Immune-Checkpoint Inhibitors in Patients with Advanced Cutaneous Squamous Cell Carcinoma: A Multicenter, Retrospective Analysis from the German ADOReg RegistryMaximilian Haist, Henner Stege, Berenice Mareen Lang, et al.
Journal of Medical Internet Research|September 11, 2020
Artificial Intelligence and Its Effect on Dermatologists' Accuracy in Dermoscopic Melanoma Image Classification: Web-Based Survey StudyRoman C Maron, Jochen S Utikal, Achim Hekler, et al.
Frontiers in Immunology|March 3, 2025
Presence of brain metastasis differentially impacts long-term survival after first-line therapy in melanoma depending on BRAF mutation statusJan-Malte Placke, Luisa Sophie Rajcsanyi, Rudolf Herbst, et al.
European Journal of Cancer (Oxford, England : 1990)|May 12, 2024
Anti-PD-1 alone or in combination with anti-CTLA-4 for advanced melanoma patients with liver metastasesInes Pires da Silva, Isabel Li, Selma Ugurel, et al.
Cancer Immunology, Immunotherapy : CII|October 28, 2021
Clinical determinants of long-term survival in metastatic uveal melanomaElias A T Koch, Anne Petzold, Anja Wessely, et al.
Cancers|November 9, 2024
Adjuvant Use of Pembrolizumab for Stage III Melanoma in a Real-World Setting in EuropeMichael Weichenthal, Joanna Mangana, Iva Gavrilova, et al.
The British Journal of Dermatology|February 20, 2026
Melanoma of unknown primary shows oncogenic pattern and clinical course of sun-exposed melanomaGeorg Lodde, Jonida Dollani, Wolfgang Galetzka, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|March 22, 2025
Early termination does not negatively impact the outcome of adjuvant immunotherapy in melanomaDirk Tomsitz, Elisabeth Livingstone, Carmen Loquai, et al.
European Journal of Cancer (Oxford, England : 1990)|July 23, 2021
Deep learning approach to predict sentinel lymph node status directly from routine histology of primary melanoma tumoursTitus J Brinker, Lennard Kiehl, Max Schmitt, et al.
Pageof 17

Showing results (81-90 of 167) with videos related to

Sort By:
Pageof 17
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 28, 2015
Intermittent High-Dose Intravenous Interferon Alfa-2b for Adjuvant Treatment of Stage III Melanoma: Final Analysis of a Randomized Phase III Dermatologic Cooperative Oncology Group TrialPeter Mohr, Axel Hauschild, Uwe Trefzer, et al.
Cancers|November 26, 2022
Response to First-Line Treatment with Immune-Checkpoint Inhibitors in Patients with Advanced Cutaneous Squamous Cell Carcinoma: A Multicenter, Retrospective Analysis from the German ADOReg RegistryMaximilian Haist, Henner Stege, Berenice Mareen Lang, et al.
Journal of Medical Internet Research|September 11, 2020
Artificial Intelligence and Its Effect on Dermatologists' Accuracy in Dermoscopic Melanoma Image Classification: Web-Based Survey StudyRoman C Maron, Jochen S Utikal, Achim Hekler, et al.
Frontiers in Immunology|March 3, 2025
Presence of brain metastasis differentially impacts long-term survival after first-line therapy in melanoma depending on BRAF mutation statusJan-Malte Placke, Luisa Sophie Rajcsanyi, Rudolf Herbst, et al.
European Journal of Cancer (Oxford, England : 1990)|May 12, 2024
Anti-PD-1 alone or in combination with anti-CTLA-4 for advanced melanoma patients with liver metastasesInes Pires da Silva, Isabel Li, Selma Ugurel, et al.
Cancer Immunology, Immunotherapy : CII|October 28, 2021
Clinical determinants of long-term survival in metastatic uveal melanomaElias A T Koch, Anne Petzold, Anja Wessely, et al.
Cancers|November 9, 2024
Adjuvant Use of Pembrolizumab for Stage III Melanoma in a Real-World Setting in EuropeMichael Weichenthal, Joanna Mangana, Iva Gavrilova, et al.
The British Journal of Dermatology|February 20, 2026
Melanoma of unknown primary shows oncogenic pattern and clinical course of sun-exposed melanomaGeorg Lodde, Jonida Dollani, Wolfgang Galetzka, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|March 22, 2025
Early termination does not negatively impact the outcome of adjuvant immunotherapy in melanomaDirk Tomsitz, Elisabeth Livingstone, Carmen Loquai, et al.
European Journal of Cancer (Oxford, England : 1990)|July 23, 2021
Deep learning approach to predict sentinel lymph node status directly from routine histology of primary melanoma tumoursTitus J Brinker, Lennard Kiehl, Max Schmitt, et al.
Pageof 17